Balyasny Asset Management’s RAPT Therapeutics RAPT Stock Holding History

Balyasny Asset Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50,348	Closed	-$1.3M	–	3480
2025 Q3	$1.3M	Buy	+50,348	New	+$659K	﹤0.01%	2006
2024 Q2	–	Sell	-7,244	Closed	-$520K	–	3006
2024 Q1	$520K	Buy	+7,244	New	+$1.01M	﹤0.01%	2033
2023 Q3	–	Sell	-18,076	Closed	-$2.7M	–	2645
2023 Q2	$2.7M	Buy	18,076 +5,418	+43%	+$844K	0.01%	1279
2023 Q1	$1.86M	Buy	+12,658	New	+$2.56M	﹤0.01%	1490
2021 Q4	–	Sell	-4,060	Closed	-$1.01M	–	2533
2021 Q3	$1.01M	Sell	4,060 -1,637	-29%	-$433K	﹤0.01%	1323
2021 Q2	$1.45M	Buy	+5,697	New	+$1.06M	0.01%	1142

Other funds holding RAPT

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Balyasny Asset Management's RAPT Position: Q4 2025 in Review

Balyasny Asset Management sold out of RAPT Therapeutics (RAPT) in Q4 2025, closing a stake of 50,348 shares — an estimated $1.3M sold.

Balyasny Asset Management first reported a position in RAPT in Q2 2021 and held it in 6 quarters. The position peaked at $2.7M in Q2 2023. 105 funds tracked by Wall St. Rank hold RAPT as of Q4 2025.

Balyasny Asset Management reported no remaining RAPT Therapeutics position as of Q4 2025 after selling out during the quarter.
Balyasny Asset Management sold 50,348 RAPT Therapeutics shares in Q4 2025, an estimated $1.3M.
Balyasny Asset Management first reported a position in RAPT Therapeutics in Q2 2021 and held it in 6 quarters.
Balyasny Asset Management's RAPT Therapeutics position peaked at $2.7M in Q2 2023.
105 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.